

GENFIT TO PRESENT AT BIO-EUROPE 2009

IN VIENNA, AUSTRIA, THE COMPANY WILL PRESENT ITS MOST ADVANCED PROGRAMS AND ITS GLOBAL IN-LICENSING STRATEGY TO TOP PHARMACEUTICAL COMPANIES

Lille (France), Cambridge (Massachusetts, United States), November 2nd, 2009 – GENFIT (Alternext : ALGFT ; ISIN : FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced its presence at BIO-Europe 2009, Europe's largest partnering conference, held in Vienna, Austria from today until November 4th.

During this international event, GENFIT will present:

- The strategic clinical positioning of GFT505 as a new drug for the preventive treatment of pre-diabetic and diabetic patients, and also for microvascular complications in diabetic patients,
- The potential of biomarkers for the early detection of atherosclerosis («BMGFT01» program) and neurodegenerative diseases («BMGFT03» program) as new tools for the follow-up of product development from the preclinical stage up to phase II and III,
- The global in-licensing strategy deployed by the company towards biotechnology companies and top pharmaceutical laboratories.

GENFIT will also give a presentation during the plenary session on Wednesday, November 4th, 2009, at 11:45 AM.

Jean-François Mouney, Chairman of the Management Board of GENFIT, announced: «This year the BIO-Europe conference promises to be very exciting. Beyond our ongoing discussions with major industrials towards a deal on GFT505, our most advanced drug candidate, for which new clinical results will soon be revealed, the major breakthroughs recorded by our teams in the field of biomarkers provide us with numerous partnership possibilities. Our product pipeline corresponds to poorly addressed therapeutic issues, thus providing a solid basis for our sustained growth.»

About GENFIT:

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer's...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT's proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT's lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS (AVE0897) and SOLVAY (SLV341), are in the advanced stages of Phase I.

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has about 130 employees, including over 100 scientists. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).

www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board

+33 (0)3 20 16 40 00

MILESTONES – Press Relations

Bruno Arabian

+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - barabian@milestones.fr

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.